MOR agonist-5 is a selective and potent mu-opioid receptor (MOR) agonist with an EC50 of 0.25 nM. MOR agonist-5 shows an EC50 of 10 nM for DOR and >10000 nM for KOR and NOR. MOR agonist-5 exerts significant antinociceptive activity. MOR agonist-5 can be used for the research of pain.

N6-Hydroxynorvalylcarbamoyladenosine (hn6A) (compound 1) is a nucleoside discovered in unfractionated tRNA from Thermodesulfobacterium commune. N6-Hydroxynorvalylcarbamoyladenosine is a modified nucleoside.

Mono-13(Z),16(Z)-docosadienoin is an acylglycerol.

MNA 279 (X 910279) is an orally active, immunosuppressive malononitrilamide and A 771726 derivative. MNA 279 suppresses IgM and IgG antibody production. MNA 279 prevents the development of systemic lupus erythematosus (SLE)-like disease in mice. MNA 279 prolongs skin xenograft survival in a mouse-to-rat model.

ML133 is a selective Kir2 family channels inhibitor, with an IC50 of 1.8 μM at pH 7.4 and 290 nM at pH 8.5.

MKI-3 is a selective microtubule-associated serine/threonine kinase-like (MASTL) inhibitor with an IC50 of 5.72 nM and a Kd of 1.89 nM. MKI-3 disrupts the MASTL-ENSA-Aurora A signaling axis. MKI-3 induces chromosomal instability, mitotic catastrophe and apoptosis (apoptosis) in cancer cells. MKI-3 is applicable to research related to triple-negative breast cancer.

m-Iodobenzylguanidine (Iobenguane) is a ligand with high affinity against norepinephrine transporter (NET). m-Iodobenzylguanidine is used as an imaging agent in the diagnostic imaging and radionuclide studies of neuroendocrine tumors, such as neuroblastoma, pheochromocytoma and carcinoid tumor.

MGAT2-IN-7 (compound 27Q) is a substituted benzenesulfonamide compound and also a monoacylglycerol acyltransferase 2 (MGAT2) inhibitor. MGAT2-IN-7 is used for research on obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

METTL3-IN-13 is a METTL3 inhibitor. METTL3-IN-13 is applicable to the research of multiple cancers such as hypopharyngeal squamous cell carcinoma and non-small cell lung cancer.

Methyl 8(Z),11(Z),14(Z),17(Z),20(Z)-tricosapentaenoate is an unsaturated fatty acid methyl ester (FAME)。

Methyl 7(E)-nonadecenoate is an unsaturated fatty acid methyl ester (FAME)。

Methyl 6(Z),9(Z),12(Z),15(Z),18(Z)-tetracosapentaenoate is an unsaturated fatty acid methyl ester (FAME)。

Methyl 5-aminovalerate hydrochloride is a PROTAC linker that can be used in the synthesis of PROTACs.

Methyl 10(Z),13(Z),16(Z)-docosatrienoate is an unsaturated fatty acid methyl ester (FAME)。

Menin-MLL-IN-37 is an orally active Menin-MLL protein complex inhibitor with an IC50 of 820.50 nM. Menin-MLL-IN-37 disrupts the interaction between menin and MLL proteins. Menin-MLL-IN-37 induces differentiation of acute myeloid leukemia cells and selectively inhibits the proliferation of MLL-rearranged and DNMT3A/NPM1-mutant leukemia cells. Menin-MLL-IN-37 can be used for the research of acute myeloid leukemia (AML).

Memagal is an AchE inhibitor (IC50 = 1.16 nM) and a NMDAR antagonist (Ki = 4.6 μM). Memagal inhibits the neurotoxicity induced by NMDA, with its IC50 value being 0.28 nM. Memagal can be used for research on Alzheimer's disease.

MEK-IN-9 (Compound 4-82) is a MEK inhibitor. MEK-IN-9 induces p15 and p27 protein. MEK-IN-9 can be used in the research of renal adenocarcinoma and colorectal cancer.

Meayamycin B ((+)-Meayamycin B) is a potent SF3B1 inhibitor. Meayamycin B upregulates the proapoptotic Mcl-1S and downregulates Mcl-1L at the pre-mRNA splicing level. Meayamycin B does not regulate the alternative splicing of Bcl-x. Meayamycin B and ABT-737 synergistically causes Apoptosis. Meayamycin B exhibits anticancer activity against non-small cell lung cancer.

MDH2-IN-2 is an orally active MDH2 inhibitor with an IC50 of 5.9 μM. MDH2-IN-2 reduces the levels of senescence markers and senescence-associated secretory phenotype (SASP) factors in mammalian cell models. MDH2-IN-2 extends the lifespan and improves the healthspan of *Caenorhabditis elegans*. MDH2-IN-2 alleviates tissue senescence in aged mice, inhibits SASP factors, and restores liver and kidney functions. MDH2-IN-2 is applicable for senescence-related research.

MC-GGFG-3-Methylenecyclobutyl (compound L-7B) is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Mc-Asn-Asn-E104 is a conjugate of E104 and a legumain-cleavable linker, can be used for the synthesis of E104 ISACs.

Mc-Asn-Asn is a legumain cleavable linker for antibody-drug conjugates (ADCs) which couples the antibody element to the effecting compound. Mc-Asn-Asn can be used in the synthesis of ADCs.

Mardepodect precursor is the precursor of Mardepodect. Mardepodect precursor. Mardepodect is a potent, selective orally active, and brain-penetrant PDE10A inhibitor with an IC50 of 0.37 nM, with >1000-fold selectivity over other PDEs.

Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE (Compound 31) is a Drug-Linker Conjugates for ADC. Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB-MMAE is composed of MMAE and Mal-Cyclobutane-1,1-dicarboxamide-Cit-PAB carbonic acid .

Mafoprazine methanesulfonate is a phenylpiperazine derivative with variable affinities for neuronal receptors. It may exert its antipsychotic effects primarily through D2 receptor blockade and α-adrenergic activity, and may increase the activity of dopamine metabolites.

M4K-2009 is an BBB-penetrant inhibitor of ALK2 with an IC50 of 13 nM. M4K-2009 is an analogue of LDN-214117. M4K-2009 is also active against the hERG potassium channel.

Lys-PEG3-BA is an EML4-ALK/EGFR PROTAC degrader with DC50 values of 1.32 and 19.66 μM for H3122 (EML4-ALK) and H1975 (EGFR-L858R/T790M) cells, respectively. Lys-PEG3-BA hinders proliferation via rewiring the ubiquitin- proteasome system in vitro. Lys-PEG3-BA can be used for non-small cell lung cancer research.

LY-33169 is an antitumor agent. LY-33169 had selective cytotoxicity against Colon Adenocarcinoma-38, Human Colon-116, Human Prostate LNCaP, and Human Breast WSU-Br-1 cells.

LY 78335 (DCMB) is a brain-penetrant phenylethanolamine-N-methyltransferase (PNMT) inhibitor with a Ki of 0.09 μM. LY 78335 acts as an α₂-adrenoceptor inhibitor with an IC50 of 10 μM. LY 78335 increases spontaneous locomotor activity in rats. LY 78335 increases extracellular concentration of 3-methoxy-4-hydroxyphenylglycol (MHPG) in rat hypothalamus. LY 78335 prevents growth hormone (GH) secretion in rats. LY 78335 can be used for the research of depression.

LXR modulator-1 (Compound 21/3) is a LXR modulator with an EC50 of less than 100 nM. LXR modulator-1 can be used for studying LXR-mediated diseases such as non-alcoholic fatty liver disease.